Clinical Trial News and Research

RSS

Exact Sciences first quarter net loss increases to $10.6 million

Exact Sciences Corp. today announced its financial results for the quarter ended March 31, 2012.

2 May 2012

InSite Vision first quarter total revenues decrease to $2.3 million

InSite Vision Incorporated today reported financial results for the quarter ended March 31, 2012. Total revenues for the first quarter of 2012 were $2.3 million, a decrease of $0.8 million from the same quarter of 2011.

2 May 2012

Gilead commences GS-1101 Phase 3 trial in CLL

Gilead Sciences, Inc. today announced that the first patient has been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-1101.

2 May 2012

ACE inhibitors or ARBs could treat and prevent PTSD

Traumatized people who take a class of common blood pressure medications tend to have less severe post-traumatic stress symptoms, researchers have found.

2 May 2012

FDA clears ProUroCare’s new prostate mechanical imaging system

ProUroCare Medical Inc., provider of proprietary medical imaging products, announced today it has received clearance from the U.S. Food & Drug Administration (FDA) for its ProUroScan prostate mechanical imaging (PMI) system.

2 May 2012

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

30 Apr 2012

Only few clinical trials are being conducted to test drugs in pediatric patients

Although children are more likely than adults to suffer from many diseases, few clinical trials are being conducted to test drugs in pediatric patients, according to a study to be presented Saturday, April 28, at the Pediatric Academic Societies (PAS) annual meeting in Boston.

30 Apr 2012

Novel liquid drug used successfully in a heart attack patient

They did the first procedure of its kind by injecting the dissolvable liquid device into a patient - a Victorian grandmother. The device flows to the damaged heart muscle and helps it repair. The liquid is derived from seaweed and was injected into Pauline Fulton's heart, a fortnight ago, two days after she suffered a major heart attack.

29 Apr 2012

Hemodiafiltration does not improve kidney failure patients' survival or heart health

A technique that removes additional toxins during dialysis does not improve kidney failure patients' survival or heart health, but intense treatments may provide a benefit, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

27 Apr 2012

Combination of Velcade and Fasudil could treat NSCLC

A common cancer drug and a drug used for a rare condition affecting the heart could together treat an aggressive form of lung cancer called non-small cell lung cancer (NSCLC), according to a study published in Cell today.

27 Apr 2012

Researchers examines whether MRI can improve accuracy of Huntington’s diagnosis

Huntington disease (HD) is an inherited neurodegenerative disorder caused by a defect on chromosome four where, within the Huntingtin gene, a CAG repeat occurs too many times. Most individuals begin experiencing symptoms in their 40s or 50s, but studies have shown that significant brain atrophy occurs several years prior to an official HD diagnosis. As a result, the field has sought a preventive treatment that could be administered prior to the development of actual symptoms that might delay the onset of illness.

27 Apr 2012

New URMC trial to evaluate carvedilol for high blood pressure

Researchers at the University of Rochester Medical Center are testing whether different doses of an established blood pressure medication can provide the same benefits as a standard dose in people with mild hypertension, possibly with fewer side effects and at a lower cost. The newly launched clinical trial, funded with a $1.9 million grant from the National Heart Lung and Blood Institute, is the first of its kind in the United States.

27 Apr 2012

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.

27 Apr 2012

Novartis receives FDA approval for Afinitor to treat renal angiomyolipomas caused by TSC

The U.S. Food and Drug Administration approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex.

27 Apr 2012

International Microbicides Conference 2012 concludes

The conclusion of the 2012 International Microbicides Conference, a gathering of researchers, advocates and funders in the HIV prevention field, wrapped up three days of discussion focused on access to prevention technologies, adherence in clinical trials, innovative financing, dual prevention technologies and new methods of preventing rectal transmission of HIV.

26 Apr 2012

CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas (PDA) who have progressed after receiving two prior therapies.

26 Apr 2012

ASIA honors SCI researchers with 2012 Apple Award

American Spinal Injury Association (ASIA) has awarded its 2012 Apple Award to the article by Mark Nash, PhD, et al, entitled, "Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial."

26 Apr 2012

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.

26 Apr 2012

Clinical and Translational Science Institute-Children's National awards pilot grant to GW researchers

GW researchers in the School of Medicine, Jeffrey M. Bethony, Ph.D., Associate Professor of Microbiology, Immunology, and Tropical Medicine and David Diemert, M.D., FRCP(C), Associate Research Professor of Microbiology, Immunology, and Tropical Medicine and Director of Clinical Trials for the Sabin Vaccine Institute's Product Development Partnership (PDP), have been awarded a Pilot Grant from the Clinical and Translational Science Institute-Children's National.

25 Apr 2012

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA).

25 Apr 2012

Clinical Trial News and Research

Exact Sciences first quarter net loss increases to $10.6 million

InSite Vision first quarter total revenues decrease to $2.3 million

Gilead commences GS-1101 Phase 3 trial in CLL

ACE inhibitors or ARBs could treat and prevent PTSD

FDA clears ProUroCare’s new prostate mechanical imaging system

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

Only few clinical trials are being conducted to test drugs in pediatric patients

Novel liquid drug used successfully in a heart attack patient

Hemodiafiltration does not improve kidney failure patients' survival or heart health

Combination of Velcade and Fasudil could treat NSCLC

Researchers examines whether MRI can improve accuracy of Huntington’s diagnosis

New URMC trial to evaluate carvedilol for high blood pressure

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

Novartis receives FDA approval for Afinitor to treat renal angiomyolipomas caused by TSC

International Microbicides Conference 2012 concludes

CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

ASIA honors SCI researchers with 2012 Apple Award

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Clinical and Translational Science Institute-Children's National awards pilot grant to GW researchers

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer